Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial

PURPOSE: In the phase III METEOR trial (ClinicalTrials.gov identifier: NCT01865747), 658 previously treated patients with advanced renal cell carcinoma were randomly assigned 1:1 to receive cabozantinib or everolimus. The cabozantinib arm had improved progression-free survival, overall survival, and...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Cella, David, Escudier, Bernard, Tannir, Nizar M., Powles, Thomas, Donskov, Frede, Peltola, Katriina, Schmidinger, Manuela, Heng, Daniel Y.C., Mainwaring, Paul N., Hammers, Hans J., Lee, Jae Lyun, Roth, Bruce J., Marteau, Florence, Williams, Paul, Baer, John, Mangeshkar, Milan, Scheffold, Christian, Hutson, Thomas E., Pal, Sumanta, Motzer, Robert J., Choueiri, Toni K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2018
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804841/
https://ncbi.nlm.nih.gov/pubmed/29377755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.2170
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller